ChainGPT's robot mascot. IMAGE: CHAINGPT
A step forward that could influence how smart contracts are designed and verified.
Updated
November 27, 2025 3:26 PM
ChainGPT's robot mascot. IMAGE: CHAINGPT
A new collaboration between ChainGPT, an AI company specialising in blockchain development tools and Secret Network, a privacy-focused blockchain platform, is redefining how developers can safely build smart contracts with artificial intelligence. Together, they’ve achieved a major industry first: an AI model trained exclusively to write and audit Solidity code is now running inside a Trusted Execution Environment (TEE). For the blockchain ecosystem, this marks a turning point in how AI, privacy and on-chain development can work together.
For years, smart-contract developers have faced a trade-off. AI assistants could speed up coding and security reviews, but only if developers uploaded their most sensitive source code to external servers. That meant exposing intellectual property, confidential logic and even potential vulnerabilities. In an industry where trust is everything, this risk held many teams back from using AI at all.
ChainGPT’s Solidity-LLM aims to solve that problem. It is a specialised large language model trained on over 650,000 curated Solidity contracts, giving it a deep understanding of how real smart contracts are structured, optimised and secured. And now, by running inside SecretVM, the Confidential Virtual Machine that powers Secret Network’s encrypted compute layer, the model can assist developers without ever revealing their code to outside parties.
“Confidential computing is no longer an abstract concept,” said Luke Bowman, COO of the Secret Network Foundation. “We've shown that you can run a complex AI model, purpose-built for Solidity, inside a fully encrypted environment and that every inference can be verified on-chain. This is a real milestone for both privacy and decentralised infrastructure”.
SecretVM makes this workflow possible by using hardware-backed encryption to protect all data while computations take place. Developers don’t interact with the underlying hardware or cryptography. Instead, they simply work inside a private, sealed environment where their code stays invisible to everyone except them—even node operators. For the first time, developers can generate, test and analyse smart contracts with AI while keeping every detail confidential.
This shift opens new possibilities for the broader blockchain community. Developers gain a private coding partner that can streamline contract logic or catch vulnerabilities without risking leaks. Auditors can rely on AI-assisted analysis while keeping sensitive audit material protected. Enterprises working in finance, healthcare or governance finally have a path to adopt AI-driven blockchain automation without raising compliance concerns. Even decentralised organisations can run smart-contract agents that make decisions privately, without exposing internal logic on a public chain.
The system also supports secure model training and fine-tuning on encrypted datasets. This enables collaborative AI development without forcing anyone to share raw data—a meaningful step toward decentralised and privacy-preserving AI at scale.
By combining specialised AI with confidential computing, ChainGPT and Secret Network are shifting the trust model of on-chain development. Instead of relying on centralised cloud AI services, developers now have a verifiable, encrypted environment where they keep full control of their code, their data and their workflow. It’s a practical solution to one of blockchain’s biggest challenges: using powerful AI tools without sacrificing privacy.
As the technology evolves, the roadmap includes confidential model fine-tuning, multi-agent AI systems and cross-chain use cases. But the core advancement is already clear: developers now have a way to use AI for smart contract development that is fast, private and verifiable—without compromising the security standards that decentralised systems rely on.
Keep Reading
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 28, 2025 4:18 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.